RIPK1: Inflamed if you do, inflamed if you don’t
Immunity · 2024-07 · 57 (7) · 1443-1445
DOI: 10.1016/j.immuni.2024.06.002 ↗Kurz gefasst
Kommentar in der Zeitschrift Immunity, 2024-07. Verfasst von Nicholas W Hubbard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, University of Utah, Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
RIPK1 is known as a driver of cell death and inflammation. In this issue of Immunity, Imai et al. and Mannion et al. find that these same processes are also induced by RIPK1 inactivation and highlight the therapeutic potential of RIPK1 elimination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, University of Utah, Salt Lake City, UT, USA.
- Department of Immunology, University of Washington, Seattle, WA, USA. Electronic address: oberst@uw.edu.
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Hubbard, N. W., & Oberst, A. (2024). RIPK1: Inflamed if you do, inflamed if you don’t. Immunity, 57(7), 1443-1445. https://doi.org/10.1016/j.immuni.2024.06.002
Vancouver
Hubbard NW, Oberst A. RIPK1: Inflamed if you do, inflamed if you don’t. Immunity. 2024;57(7):1443-1445. doi:10.1016/j.immuni.2024.06.002
BibTeX
@article{Hubbard2024,
author = {Hubbard, Nicholas W and Oberst, Andrew},
title = {RIPK1: Inflamed if you do, inflamed if you don’t},
journal = {Immunity},
year = {2024},
volume = {57},
number = {7},
pages = {1443--1445},
doi = {10.1016/j.immuni.2024.06.002}
}
EUVIMED